期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 625, 期 1-3, 页码 41-54出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2009.09.067
关键词
Immunotherapy; Cancer; Monoclonal antibody; Cell-based therapy; Toll-like receptors
资金
- Centers of Research Excellence [CA06927]
- National Cancer Institute (NCI)
- National Institutes of Health
- Fox Chase Cancer Center
- [CA083859]
- [CA100226]
Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response. For instance, toll-like receptor agonists have been shown to boost immune responses toward tumors. Also, a wide array of cell-based immunotherapies utilizing T cells, NK cells, and dendritic cells have been established. Furthermore, a rapidly expanding repertoire of monoclonal antibodies is being developed to treat tumors, and many of the available antibodies have demonstrated impressive clinical responses. Here, we examine some of these immunotherapeutic approaches currently in use or testing to treat cancer, and we examine available evidence with regards to mechanism and efficacy of these treatments. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据